You need to be logged in to view this video
Biotech Investing: The Covid-19 "Delta" Variant Means the Job Is Not Done
Released on Tuesday, August 10, 2021•BIOTECH
Biotech Covid-19 vaccine development has demonstrated the power of biotech to change the world and make handsome returns for investors. With the Delta variant wrecking devastation worldwide, join this presentation to discover what's next. Can an oral vaccine be the difference maker to finally tame Covid-19?
John McCamant was named editor of the Medical Technology Stock Letter in August 2000. He has spent 35 years on the front lines of biotechnology investing as an equities analyst and in venture capital. His expertise in biotechnology investments is a subject of media interest, and he is frequently consulted and quoted by The Washington Post, BusinessWeek, Reuters, and Bloomberg.
Filter By Category
Filter By Keywords